Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 14/20 | 0.35 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 2/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24665846 | 1.00 | CFD (0.35) | CFDPSMB9EP300CREBBPS1PR3 | |
| SCHEMBL29231069 | 1.00 | CFD (0.35) | CFDPSMB9EP300CREBBPS1PR3 | |
| SCHEMBL30341463 | 1.00 | CFD (0.35) | CFDPSMB9EP300CREBBPS1PR3 | |
| SCHEMBL29820569 | 0.89 | CFD (0.37) | CFDPSMB9EP300CREBBP | |
| SCHEMBL24665847 | 0.89 | CFD (0.37) | CFDPSMB9EP300CREBBP | |
| SCHEMBL30341422 | 0.89 | CFD (0.37) | CFDPSMB9EP300CREBBP | |
| SCHEMBL29231397 | 0.89 | CFD (0.37) | CFDPSMB9EP300CREBBP | |
| SCHEMBL24665540 | 0.88 | CFD (0.36) | CFDPSMB9EP300DRD2 | |
| SCHEMBL29230579 | 0.88 | CFD (0.36) | CFDPSMB9EP300DRD2 | |
| SCHEMBL29820571 | 0.88 | CFD (0.36) | CFDPSMB9EP300DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308095-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |